Interrogative

BPGbio Announces New Partnership with DoD Focused on AI-Guided Breast Cancer Diagnostics

Retrieved on: 
Monday, May 22, 2023
Oncology, Health, Technology, Neurology, Artificial Intelligence, Pharmaceutical, Biotechnology, Windber Research Institute, Prostate cancer, BPH, Breast cancer, HJF, CBCP, Military medicine, Woman, Research, Interrogative, USU, Patient, Henry M. Jackson Foundation for the Advancement of Military Medicine, Outline of health sciences, AI, Rare, PSA, ER, Medical imaging

BPGbio’s Interrogative Biology ® Platform will complete comprehensive omics analysis and assessment using tissue and plasma/serum samples from a CBCP-supported program focused on breast cancer research.

Key Points: 
  • BPGbio’s Interrogative Biology ® Platform will complete comprehensive omics analysis and assessment using tissue and plasma/serum samples from a CBCP-supported program focused on breast cancer research.
  • The Interrogative Biology® Platform will also provide expanded assessment of BPGbio’s novel breast cancer diagnostic 34 gene panel with a focus on ER+ breast cancers, which are significantly on the rise.
  • “We are pleased to collaborate with BPGbio and use their AI and diagnostic platform to aid patients afflicted with breast cancer,” said Joseph Caravalho , Jr., M.D., HJF’s President and CEO.
  • “The BPGbio team has exceptional expertise in translating comprehensive omics analysis into effective diagnostic products for various cancer indications, which improves the lives of the patients we serve.”

BPGbio Announces Appointments to its Leadership Team to Accelerate Research and Commercialization

Retrieved on: 
Monday, March 6, 2023
Research, Technology, Infectious Diseases, Neurology, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Ethos, Innova, BMS, Service, Jawaharlal Nehru University, Credit Suisse, MBA, CSO, Thermo Fisher Scientific, Citigroup, Biogen, AstraZeneca, Engineering, Interrogative, University of Oxford, NCI, LATAM, Growth, Accounting, Celgene, USC, JPMorgan Chase, UCLA, National Cancer Institute, Biology, University of Cambridge, Lehigh University, Master of Science, Life Technologies, Innovation system, Investment, Bristol Myers Squibb, Harvard University, CFO, Translational medicine, Prudential Securities, Treasury, Master of Engineering, Pharmaceutical industry, Management, IIT Delhi, Genetics

Dr. Thakurta’s leadership and scientific contributions have led to six approved cancer drugs in multiple indications.

Key Points: 
  • Dr. Thakurta’s leadership and scientific contributions have led to six approved cancer drugs in multiple indications.
  • Prior to BPGbio, Dr. Thakurta was the Vice President, Translational Medicine at Bristol Myers Squibb where he oversaw the hematological malignancy group.
  • Before BMS, Dr. Thakurta served several leadership roles at Celgene, AstraZeneca and Biogen Idec and the United States National Cancer Institute (NCI) earlier in his career.
  • Prior to BPGbio he led strategy and investments for Innova Medical Group and was a Principal at Pasaca Capital.